{"id":"W2559804019","doi":"10.1016/s0140-6736(16)32455-2","title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2211,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre","funders":"National Cancer Institute; EMD Serono; Ipsen; Astellas Pharma; F. Hoffmann-La Roche; Eisai; Sanofi; Amgen; Pfizer; Genentech; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Atezolizumab; Medicine; Metastatic Urothelial Carcinoma; Clinical endpoint; Oncology; Internal medicine; Cisplatin; Chemotherapy; Progression-free survival; Phases of clinical research; Response Evaluation Criteria in Solid Tumors; Cancer; Bladder cancer; Urology; Clinical trial; Urothelial carcinoma; Immunotherapy; Pembrolizumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001892472,0.001550669,0.003002611,0.0002948421,0.0003166385,0.001234925,0.00090462,0.001794121,0.00361763],"category_scores_gemma":[0.001979239,0.0006058366,0.002653756,0.0003472635,0.0009809405,0.001436325,0.0004567126,0.004323485,0.0006547927],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009373963,"about_ca_system_score_gemma":0.00096325,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007439889,"about_ca_topic_score_gemma":0.002169105,"domain_scores_codex":[0.9994841,0.0002711937,0.00002347484,0.000106283,0.0000273604,0.0000875902],"domain_scores_gemma":[0.999078,0.0002536588,0.0001897753,0.00008197728,0.00004578017,0.0003508095],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9454031,0.005353887,0.002014938,0.0009417679,0.001773965,0.00009140885,0.0001222035,0.001441485,0.004150813,0.0001606662,0.002085806,0.03646013],"study_design_scores_gemma":[0.9178294,0.07554702,0.00366233,0.00004438137,0.0006422966,0.0001014034,0.00003836897,0.0006787792,0.0003589107,0.0001995061,0.0008747774,0.00002290688],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.98875,0.006020545,0.0004986688,0.001248357,0.0004784746,0.0008199819,0.0009228747,0.00008882135,0.001172403],"genre_scores_gemma":[0.9900636,0.00280691,0.0008849449,0.001355375,0.0002317087,0.0007967592,0.001427097,0.00003199667,0.002401698],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00361763,"threshold_uncertainty_score":0.01210225,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03479870827848872,"score_gpt":0.3052424545209158,"score_spread":0.2704437462424271,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}